Seattle Genetics has halted the development of Lintuzumab for treatment of acute myeloid leukaemia in older patients following poor results in a Phase IIb trial.

The monoclonal antibody, given in combination low-dose cytarabine chemotherapy, did not meet the primary endpoint of extending overall survival when compared with low-dose cytarabine chemotherapy plus a placebo.

The double-blind, multi-centre, randomised and placebo-controlled trial involved 211 patients with acute myeloid leukaemia aged 60 years and older, who were ineligible for intensive chemotherapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData